Common Questions About Recurrent Urinary Tract Infections in Women
Am Fam Physician. 2016 Apr 1;93(7):560-569.
Patient information: See related handout on recurrent urinary tract infections, written by the authors of this article.
Author disclosure: No relevant financial affiliations.
Article Sections
- Abstract
- What Are the Risk Factors for Recurrent UTIs?
- Is Susceptibility to Recurrent UTIs Inherited?
- When Is Further Clinical Evaluation Recommended?
- Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?
- What Are the Benefits of Patient-Initiated Treatment?
- Which Prophylactic Regimens Are Recommended?
- Are There Alternative Treatment Strategies to Limit Antibiotic Use?
- References
Recurrent urinary tract infections (UTIs) are common in women, including healthy women with normal genitourinary anatomy. Recurrent UTI is typically defined as three or more UTIs within 12 months, or two or more occurrences within six months. The same species that caused previous infections is typically responsible for recurrences. In premenopausal women, sexual intercourse three or more times per week, spermicide use, new or multiple sex partners, and having a UTI before 15 years of age are established risk factors. In postmenopausal women, risk is primarily increased by sequelae of lower estrogen levels. Episodes of recurrent UTI are typically characterized by dysuria and urinary frequency or hesitancy. Findings from the history or physical examination that suggest complicated infection or another disease process warrant additional evaluation. At least one symptomatic episode should be verified by urine culture to confirm the diagnosis and guide treatment. Imaging is rarely warranted. Short courses of antibiotics are as effective as longer courses. Patient-initiated treatment lowers the cost of diagnosis, number of physician visits, and number of symptomatic days compared with physician-initiated treatment. It also reduces antibiotic exposure compared with antibiotic prophylaxis. Antibiotic prophylaxis effectively limits UTI recurrence but increases the risk of antibiotic resistance and adverse effects. Cranberry products may reduce recurrent UTIs in premenopausal women, but are less effective than antibiotic prophylaxis, and data are conflicting. Optimal dosing is unknown. Postmenopausal women with atrophic vaginitis may benefit from topical estrogen therapy.
Urinary tract infections (UTIs) are the most common bacterial infection in women of all ages.1 An estimated 30% to 44% of women will have a second UTI within six months of an initial infection.2–4 Healthy women with normal urologic anatomy account for most patients who have recurrent UTIs.1–5
SORT: KEY RECOMMENDATIONS FOR PRACTICE
| Clinical recommendation | Evidence rating | References |
|---|---|---|
In patients who are candidates for prophylactic or self-initiated treatment of recurrent UTI, at least one episode should be confirmed by a urine culture demonstrating at least 102 bacterial colonies per mL of a known urinary pathogen when the patient is symptomatic. | C | |
Imaging and cystoscopy are rarely necessary in healthy women with recurrent UTIs, unless risk factors for complicated infection are present. | B | |
A three-day course of trimethoprim/sulfamethoxazole, a one-day course of fosfomycin (Monurol), or a five-day course of nitrofurantoin is as effective as longer treatment courses in achieving clinical cure of an isolated or recurrent UTI. | A | |
Both continuous daily and postcoital low-dose antibiotic prophylaxis regimens decrease recurrence of symptomatic UTIs. | A | |
Prophylaxis with daily estrogen vaginal cream in postmenopausal women may reduce the risk of future UTIs. | B | |
Prophylaxis with daily cranberry tablets may reduce the risk of future UTIs in premenopausal women, but data are conflicting. | B |
UTI = urinary tract infection.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.
SORT: KEY RECOMMENDATIONS FOR PRACTICE
| Clinical recommendation | Evidence rating | References |
|---|---|---|
In patients who are candidates for prophylactic or self-initiated treatment of recurrent UTI, at least one episode should be confirmed by a urine culture demonstrating at least 102 bacterial colonies per mL of a known urinary pathogen when the patient is symptomatic. | C | |
Imaging and cystoscopy are rarely necessary in healthy women with recurrent UTIs, unless risk factors for complicated infection are present. | B | |
A three-day course of trimethoprim/sulfamethoxazole, a one-day course of fosfomycin (Monurol), or a five-day course of nitrofurantoin is as effective as longer treatment courses in achieving clinical cure of an isolated or recurrent UTI. | A | |
Both continuous daily and postcoital low-dose antibiotic prophylaxis regimens decrease recurrence of symptomatic UTIs. | A | |
Prophylaxis with daily estrogen vaginal cream in postmenopausal women may reduce the risk of future UTIs. | B | |
Prophylaxis with daily cranberry tablets may reduce the risk of future UTIs in premenopausal women, but data are conflicting. | B |
UTI = urinary tract infection.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.
Recurrent UTI is typically defined as three or more UTIs in 12 months, or two or more infections in six months.2–5 Recurrence is thought to occur by ascent of uropathogens in fecal flora along the urogenital tract and by reemergence of bacteria from intracellular bacterial colonies in uroepithelial cells. In either mechanism, the same species that caused the initial infection is typically the reinfecting agent.5
Escherichia coli causes approximately 75% of recurrent UTIs; most other infections are caused by Enterococcus faecalis, Proteus mirabilis, Klebsiella, or Staphylococcus saprophyticus.1,2,5 This article addresses common questions about recurrent UTIs in otherwise healthy nonpregnant women.
What Are the Risk Factors for Recurrent UTIs?
- Abstract
- What Are the Risk Factors for Recurrent UTIs?
- Is Susceptibility to Recurrent UTIs Inherited?
- When Is Further Clinical Evaluation Recommended?
- Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?
- What Are the Benefits of Patient-Initiated Treatment?
- Which Prophylactic Regimens Are Recommended?
- Are There Alternative Treatment Strategies to Limit Antibiotic Use?
- References
Independent risk factors for recurrent UTIs in premenopausal women include sexual intercourse three or more times per week, spermicide use, new or multiple sex partners, and having a UTI before 15 years of age. In postmenopausal women, estrogen deficiency and urinary retention are strong contributors.
EVIDENCE SUMMARY
Frequent intercourse likely causes inoculation of the urethra and bladder by fecal flora, whereas spermicide use disrupts the healthy Lactobacillus flora of the vaginal canal, thereby allowing ascent of uropathogens.6–8 In premenopausal women, intercourse three or more times per week triples the risk of UTI.8 Well-designed case-control studies suggest that body mass index, wiping back-to-front after bowel movements, hot tub use, douching, frequent tampon use, increased hydration, and wearing cotton underwear have no effect on the risk of recurrence.5,6 Postcoital urination seems to have little protective effect but is a reasonable and safe practice.6
In otherwise healthy postmenopausal women, estrogen deficiency is a risk factor for recurrent UTIs because of changes in Lactobacillus flora and vaginal pH.9 Other risk factors in postmenopausal women include incontinence, a postvoid residual urinary volume exceeding 150 mL, structural abnormalities (e.g., cystocele), type 1 or 2 diabetes mellitus, or a history of more than five UTIs.6,9 Activities that increase intra-abdominal pressure (e.g., long-distance walking or traveling) may exacerbate incontinence, cystocele, or postvoid residual urine, and may predispose women who engage in these activities to UTIs.9,10
Is Susceptibility to Recurrent UTIs Inherited?
- Abstract
- What Are the Risk Factors for Recurrent UTIs?
- Is Susceptibility to Recurrent UTIs Inherited?
- When Is Further Clinical Evaluation Recommended?
- Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?
- What Are the Benefits of Patient-Initiated Treatment?
- Which Prophylactic Regimens Are Recommended?
- Are There Alternative Treatment Strategies to Limit Antibiotic Use?
- References
Inherited factors seem to influence a woman's susceptibility to recurrent UTIs. However, such influences are largely nonmodifiable and therefore do not alter clinical recommendations.
EVIDENCE SUMMARY
Having a first-degree female relative with a history of five or more UTIs is a risk factor for recurrent UTIs.7 Specific inheritance patterns, such as nuanced neutrophil receptors and nonsecretor status of blood-type antigens, may decrease the immune system's ability to clear bacteria or prevent their attachment to uroepithelium. Furthermore, variations in urogenital tract anatomy, including a short urethral-anal distance, may predispose some women to UTIs.5–7
When Is Further Clinical Evaluation Recommended?
- Abstract
- What Are the Risk Factors for Recurrent UTIs?
- Is Susceptibility to Recurrent UTIs Inherited?
- When Is Further Clinical Evaluation Recommended?
- Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?
- What Are the Benefits of Patient-Initiated Treatment?
- Which Prophylactic Regimens Are Recommended?
- Are There Alternative Treatment Strategies to Limit Antibiotic Use?
- References
A history suggestive of uncomplicated acute cystitis in patients with a previous culture-confirmed UTI is typically sufficient for diagnosis of recurrent infection. Physical examination, laboratory testing, and imaging have limited utility and are not universally recommended.
EVIDENCE SUMMARY
Figure 1 presents a suggested approach to the evaluation and management of recurrent UTIs.3,11–17 Uncomplicated acute cystitis, including recurrent episodes, is typically characterized by a combination of dysuria, urinary frequency, and urinary hesitancy.11,12 Clinicians should be confident in a patient's self-diagnosis of recurrent UTI based on symptoms consistent with previous culture-confirmed infections. In prospective studies, patient suspicion of UTI is more than 85% accurate in predicting culture-positive infections; this is more accurate than urine dipstick testing.13,15,18–22 However, additional evaluation and treatment are warranted in patients with fever, nausea, vomiting, acute back pain, previous urogenital surgery, bladder catheterization, vaginal discharge, pelvic pain, or exposure to a sexually transmitted infection, because these may be signs of a complicated infection or another disease process.13,14,18,23 Pregnancy testing should be considered in premenopausal women. If the patient reports incontinence, overactive bladder, or incomplete bladder emptying, postvoid residual urinary volume and urodynamic testing may be helpful in guiding treatment.14,23
Evaluation and Management of Recurrent UTI
Figure 1.
Approach to low-risk, nonpregnant women with recurrent urinary tract infections (UTIs).
Patients who are candidates for prophylactic or self-initiated treatment should have at least one positive urine culture (at least 102 bacterial colonies per mL of a known urinary pathogen) while symptomatic to confirm concordance of symptoms with a true infection.3,5,11,15,17,22 Thereafter, repeat testing during recurrence of typical symptoms may increase cost and inconvenience for the patient, and subsequent benefit is unclear.11,12,17,23–25 However, repeat cultures should be obtained to establish resistance patterns in patients who have breakthrough UTIs while receiving prophylactic therapy.11,16 Cultures are warranted in patients with persistent UTI symptoms after 48 hours of antibiotic therapy, or with persistent symptomatic bacteriuria after two weeks of culture-directed antibiotic therapy because this may indicate a relapsed infection, which typically occurs because of antibiotic resistance or a persistent nidus of infection.3,11,13,18 Patients with persistent symptoms but negative cultures should be evaluated for a noninfectious cause of dysuria, such as interstitial cystitis or bladder cancer.3,11
The usefulness of pelvic examination in women with recurrent UTIs is limited; however, findings that predispose patients to complicated UTIs (e.g., cystocele, urethral diverticulum, fistula) may be detected.14,23 Imaging of the upper and lower urologic system with ultrasonography or computed tomography is typically unnecessary and should be guided by the presence of risk factors (Table 1).3,12,14,23 The diagnostic yield of cystoscopy suggesting anatomic abnormalities is less than 15%; therefore, routine cystoscopy is unwarranted.23,26–28 Cystoscopy in the setting of negative imaging findings is rarely diagnostic; therefore, noninvasive imaging should be completed first.23
Selected Factors That Warrant Further Evaluation in Patients with Recurrent Urinary Tract Infections
Hematuria (macroscopic or microscopic) persisting after clearance of infection, noted by resolution of symptoms or a negative urine culture |
History of urinary tract malignancy |
History of urinary tract surgery or trauma, or diverticular disease |
History or presence of calculi* |
Multidrug-resistant organism |
Persistent symptoms and bacteriuria despite two weeks of culture-directed therapy |
Pneumaturia or fecaluria |
Presence of anaerobic organisms (with the exception of facultative anaerobes [e.g., Escherichia coli, Staphylococcus species]) |
Repeat episodes of pyelonephritis or treatment-resistant pyelonephritis |
Symptoms of urinary obstruction |
Voiding dysfunction (e.g., elevated postvoid residual volume, incontinence) |
Selected Factors That Warrant Further Evaluation in Patients with Recurrent Urinary Tract Infections
Hematuria (macroscopic or microscopic) persisting after clearance of infection, noted by resolution of symptoms or a negative urine culture |
History of urinary tract malignancy |
History of urinary tract surgery or trauma, or diverticular disease |
History or presence of calculi* |
Multidrug-resistant organism |
Persistent symptoms and bacteriuria despite two weeks of culture-directed therapy |
Pneumaturia or fecaluria |
Presence of anaerobic organisms (with the exception of facultative anaerobes [e.g., Escherichia coli, Staphylococcus species]) |
Repeat episodes of pyelonephritis or treatment-resistant pyelonephritis |
Symptoms of urinary obstruction |
Voiding dysfunction (e.g., elevated postvoid residual volume, incontinence) |
Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?
- Abstract
- What Are the Risk Factors for Recurrent UTIs?
- Is Susceptibility to Recurrent UTIs Inherited?
- When Is Further Clinical Evaluation Recommended?
- Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?
- What Are the Benefits of Patient-Initiated Treatment?
- Which Prophylactic Regimens Are Recommended?
- Are There Alternative Treatment Strategies to Limit Antibiotic Use?
- References
Uncomplicated infections can be treated with a three-day course of trimethoprim/sulfamethoxazole, a five-day course of nitrofurantoin, or a one-day course of fosfomycin (Monurol)1,29–32; these regimens are preferred to fluoroquinolones to minimize antibiotic resistance. Beta-lactams are less effective. Recommended regimens are the same for women with diabetes.
EVIDENCE SUMMARY
Patients with recurrent UTIs may be at higher risk of non–E. coli infection compared with those who have isolated acute cystitis.33 However, both disease processes are caused by similar pathogens and are treated according to local resistance patterns, patient factors, and drug availability (Table 2).1,3,5,11,12,21,23,29–32,34–36 Compared with longer treatment durations, three-day courses of bactericidal antimicrobials are associated with fewer adverse effects, improved treatment adherence, and similarly low risk of progression to pyelonephritis (less than 1%).11,29–31
Treatment Regimens for Uncomplicated Acute Cystitis and Recurrent Urinary Tract Infections
| Antibiotic | Dosage | Effectiveness (%) | Resistance rate (%)* | Cautions and contraindications | Adverse effects | Cost† | U.S. Food and Drug Administration pregnancy category | Comments | Infectious Diseases Society of America recommendation | |
|---|---|---|---|---|---|---|---|---|---|---|
First-line agents | ||||||||||
Fosfomycin (Monurol) | 3-g packet one time | 91 | Up to 0.6 | Hypersensitivity to fosfomycin, suspected pyelonephritis | Diarrhea, headache, nausea, vaginitis | NA ($69) | B | Minimal change in gut flora; effective against methicillin-resistant Staphylococcus aureus, ESBL-producing organisms, Enterococcus faecalis, vancomycin-resistant Enterococcus | Single dose is appropriate for acute cystitis despite concerns about effectiveness | |
Nitrofurantoin | 100 mg two times per day for five days | 93 | Up to 1.6 | Glomerular filtration rate less than 40 to 60 mL per minute, history of cholestatic jaundice or hepatic dysfunction with previous use, pregnancy (greater than 38 weeks' gestation), pulmonary or hepatic fibrosis, suspected pyelonephritis; use with caution in patients with G6PD deficiency | Flatus, headache, hemolytic anemia, nausea, neuropathy; risk of pulmonary and hepatic fibrosis with long-term use | $19 (NA) | B | Minimal change in gut flora; should be taken with meals; may turn urine orange; effective against E. faecalis, S. aureus, and Staphylococcus saprophyticus | Five-day course is as effective as three-day course of trimethoprim/ sulfamethoxazole for treatment of acute cystitis | |
Trimethoprim/ sulfamethoxazole | 160/800 mg two times per day for three days | 93 | Up to 24.2 | History of drug-induced thrombocytopenia or other hematologic disorder, local resistance rates greater than 20%, pregnancy, sulfa allergy, use in previous three to six months; use with caution in patients with hepatic or renal impairment, porphyria, or G6PD deficiency | Bone marrow suppression, electrolyte abnormalities, hepatotoxicity, nausea, nephrotoxicity, photosensitivity, rash, Stevens-Johnson syndrome | $4 (NA) | D | Alters gut flora | Three-day course is appropriate if local resistance rates do not exceed 20% | |
Second-line agents | ||||||||||
Fluoroquinolones (e.g., ciprofloxacin, levofloxacin [Levaquin]) |
| 90 |
| Concurrent use with medications that prolong QT interval, hypokalemia, hypomagnesemia, local resistance rates greater than 10%, myasthenia gravis, pregnancy; use with caution in patients with renal impairment | Diarrhea, drowsiness, headache, insomnia, nausea, QT interval prolongation, tendon rupture |
| C | Alters gut flora; ciprofloxacin is preferred over other fluoroquinolones; limit use to patients with pyelonephritis or resistant cystitis | Three-day course is highly effective for treatment of cystitis; reserve for treatment of more severe conditions (e.g., pyelonephritis) | |
Alternative agents if first- and second-line agents are contraindicated | ||||||||||
Beta-lactams (e.g., amoxicillin/clavulanate [Augmentin], cefaclor, cefdinir, cefpodoxime, cephalexin [Keflex]) |
| 89 | Varies by medication | Cephalosporin or penicillin allergy, history of cholestatic jaundice with previous use; use with caution in patients with renal or hepatic impairment, history of infectious colitis, or active mononucleosis; use cephalexin with caution in patients with elevated international normalized ratios | Diarrhea (including Clostridium difficile colitis), headache, hepatotoxicity, nausea, rash, vaginitis |
| B | Alters gut flora; use with caution because of increasing prevalence of ESBL-producing Escherichia coli | Courses of three to seven days are appropriate if other agents cannot be used; fewer supporting data for cephalexin; high resistance rates should preclude use of amoxicillin | |
ESBL = extended-spectrum beta-lactamase; G6PD = glucose-6-phosphate dehydrogenase; NA = not available.
*—Resistance information is based on averages from one large 2010 multicenter analysis of 12 million outpatient cultures obtained throughout the United States.35 Fosfomycin resistance is difficult to ascertain because most laboratories do not routinely test its susceptibility. However, one international multicenter study found resistance rates of 0.6%,34 and its effectiveness was demonstrated in a 2010 meta-analysis.32 Local resistance rates may vary.
†—Estimated retail cost for one course of therapy based on information obtained at http://www.goodrx.com (accessed July 21, 2015). Cost for generic listed first; brand name in parentheses, when available.
Treatment Regimens for Uncomplicated Acute Cystitis and Recurrent Urinary Tract Infections
| Antibiotic | Dosage | Effectiveness (%) | Resistance rate (%)* | Cautions and contraindications | Adverse effects | Cost† | U.S. Food and Drug Administration pregnancy category | Comments | Infectious Diseases Society of America recommendation | |
|---|---|---|---|---|---|---|---|---|---|---|
First-line agents | ||||||||||
Fosfomycin (Monurol) | 3-g packet one time | 91 | Up to 0.6 | Hypersensitivity to fosfomycin, suspected pyelonephritis | Diarrhea, headache, nausea, vaginitis | NA ($69) | B | Minimal change in gut flora; effective against methicillin-resistant Staphylococcus aureus, ESBL-producing organisms, Enterococcus faecalis, vancomycin-resistant Enterococcus | Single dose is appropriate for acute cystitis despite concerns about effectiveness | |
Nitrofurantoin | 100 mg two times per day for five days | 93 | Up to 1.6 | Glomerular filtration rate less than 40 to 60 mL per minute, history of cholestatic jaundice or hepatic dysfunction with previous use, pregnancy (greater than 38 weeks' gestation), pulmonary or hepatic fibrosis, suspected pyelonephritis; use with caution in patients with G6PD deficiency | Flatus, headache, hemolytic anemia, nausea, neuropathy; risk of pulmonary and hepatic fibrosis with long-term use | $19 (NA) | B | Minimal change in gut flora; should be taken with meals; may turn urine orange; effective against E. faecalis, S. aureus, and Staphylococcus saprophyticus | Five-day course is as effective as three-day course of trimethoprim/ sulfamethoxazole for treatment of acute cystitis | |
Trimethoprim/ sulfamethoxazole | 160/800 mg two times per day for three days | 93 | Up to 24.2 | History of drug-induced thrombocytopenia or other hematologic disorder, local resistance rates greater than 20%, pregnancy, sulfa allergy, use in previous three to six months; use with caution in patients with hepatic or renal impairment, porphyria, or G6PD deficiency | Bone marrow suppression, electrolyte abnormalities, hepatotoxicity, nausea, nephrotoxicity, photosensitivity, rash, Stevens-Johnson syndrome | $4 (NA) | D | Alters gut flora | Three-day course is appropriate if local resistance rates do not exceed 20% | |
Second-line agents | ||||||||||
Fluoroquinolones (e.g., ciprofloxacin, levofloxacin [Levaquin]) |
| 90 |
| Concurrent use with medications that prolong QT interval, hypokalemia, hypomagnesemia, local resistance rates greater than 10%, myasthenia gravis, pregnancy; use with caution in patients with renal impairment | Diarrhea, drowsiness, headache, insomnia, nausea, QT interval prolongation, tendon rupture |
| C | Alters gut flora; ciprofloxacin is preferred over other fluoroquinolones; limit use to patients with pyelonephritis or resistant cystitis | Three-day course is highly effective for treatment of cystitis; reserve for treatment of more severe conditions (e.g., pyelonephritis) | |
Alternative agents if first- and second-line agents are contraindicated | ||||||||||
Beta-lactams (e.g., amoxicillin/clavulanate [Augmentin], cefaclor, cefdinir, cefpodoxime, cephalexin [Keflex]) |
| 89 | Varies by medication | Cephalosporin or penicillin allergy, history of cholestatic jaundice with previous use; use with caution in patients with renal or hepatic impairment, history of infectious colitis, or active mononucleosis; use cephalexin with caution in patients with elevated international normalized ratios | Diarrhea (including Clostridium difficile colitis), headache, hepatotoxicity, nausea, rash, vaginitis |
| B | Alters gut flora; use with caution because of increasing prevalence of ESBL-producing Escherichia coli | Courses of three to seven days are appropriate if other agents cannot be used; fewer supporting data for cephalexin; high resistance rates should preclude use of amoxicillin | |
ESBL = extended-spectrum beta-lactamase; G6PD = glucose-6-phosphate dehydrogenase; NA = not available.
*—Resistance information is based on averages from one large 2010 multicenter analysis of 12 million outpatient cultures obtained throughout the United States.35 Fosfomycin resistance is difficult to ascertain because most laboratories do not routinely test its susceptibility. However, one international multicenter study found resistance rates of 0.6%,34 and its effectiveness was demonstrated in a 2010 meta-analysis.32 Local resistance rates may vary.
†—Estimated retail cost for one course of therapy based on information obtained at http://www.goodrx.com (accessed July 21, 2015). Cost for generic listed first; brand name in parentheses, when available.
Persistent bacteriuria after resolution of clinical symptoms should be considered asymptomatic bacteriuria and should not be further treated in nonpregnant women.37,38 Furthermore, treatment of asymptomatic bacteriuria may increase the risk of UTI recurrence by altering normal flora.37,38
Although UTIs in women with diabetes have historically been classified as complicated,3,23 new limited data suggest that causative pathogens and resistance rates are comparable to those of UTIs in women without diabetes.39–41 Two recent systematic reviews suggest that UTIs in women with diabetes should be treated in the same manner as those in women without diabetes unless risk factors for functionally or anatomically altered voiding are present.11,20
What Are the Benefits of Patient-Initiated Treatment?
- Abstract
- What Are the Risk Factors for Recurrent UTIs?
- Is Susceptibility to Recurrent UTIs Inherited?
- When Is Further Clinical Evaluation Recommended?
- Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?
- What Are the Benefits of Patient-Initiated Treatment?
- Which Prophylactic Regimens Are Recommended?
- Are There Alternative Treatment Strategies to Limit Antibiotic Use?
- References
Patient-initiated treatment lowers the cost of diagnosis, physician visits, and symptomatic days compared with physician-initiated treatment, and reduces antibiotic exposure compared with antibiotic prophylaxis.
EVIDENCE SUMMARY
No reduction in UTI episodes is achieved when patients initiate treatment. However, compared with prophylactic strategies or physician-initiated treatment, this approach seems to minimize the physiologic and financial cost of frequent antibiotic use, cost of diagnosis, number of physician visits, and number of symptomatic days, by limiting doses to symptomatic events.12,15,19,23–25,42
Which Prophylactic Regimens Are Recommended?
- Abstract
- What Are the Risk Factors for Recurrent UTIs?
- Is Susceptibility to Recurrent UTIs Inherited?
- When Is Further Clinical Evaluation Recommended?
- Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?
- What Are the Benefits of Patient-Initiated Treatment?
- Which Prophylactic Regimens Are Recommended?
- Are There Alternative Treatment Strategies to Limit Antibiotic Use?
- References
Continuous daily and postcoital low-dose antibiotic prophylactic regimens decrease recurrence of symptomatic UTIs by approximately 95%, although patients may revert to preprophylaxis recurrence rates once prophylaxis is discontinued. 5,11,16
EVIDENCE SUMMARY
A large meta-analysis conducted in 2004 demonstrated that clinical recurrence of UTI is greatly reduced during antibiotic prophylaxis (relative risk [RR] = 0.15; 95% confidence interval [CI], 0.08 to 0.28; number needed to treat = 2).16 However, once prophylaxis was discontinued, patients reverted to pretreatment frequency of UTI.16
Clinicians should be mindful of local resistance patterns, patient factors, and drug availability when selecting the antimicrobial agent. Regimens have similar effectiveness, and all may lead to gastrointestinal upset, vaginal candidiasis, and rash.16
Compared with daily prophylaxis, postcoital prophylaxis reduces the total amount of antibiotics used without compromising effectiveness.5,10,11,16 This approach may be appropriate for patients with intercourse-associated UTIs, and may further limit antibiotic exposure in patients who have infrequent intercourse.3,5,10,11,16 Data suggest that intracellular bacterial communities coalesce as early as three hours after inoculation into the bladder; accordingly, antibiotics taken within two hours of intercourse may be optimal to prevent UTIs.5
The optimal duration of antibiotic prophylaxis is unknown. Based on consensus opinion and limited data, an initial six- to 12-month course should be offered.3,11,16 Small studies have shown effectiveness for up to five years, although long-term adverse effects such as antibiotic resistance and reversible pulmonary fibrosis from several years of nitrofurantoin use have been reported.3 Common dosing options for antibiotic prophylaxis are listed in Table 3.3,12,14,16,23
Recommended Prophylactic Regimens for Recurrent Urinary Tract Infections
| Medication | Continuous dosage | Postcoital dose | Cost* |
|---|---|---|---|
Commonly used first-line agents | |||
Nitrofurantoin | 50 to 100 mg per day | 100 mg | $29 to $45 (NA) |
Trimethoprim/sulfamethoxazole | 40/200 mg (one-half of an 80/400-mg tablet) per day or 40/200 mg three times per week (alternative) | 40/200 mg or 80/400 mg | $4 to $6 (NA) |
Occasionally used first-line agents | |||
Cefaclor | 250 mg per day | — | $47 (NA) |
Cephalexin (Keflex) | 125 to 250 mg per day | 250 mg | $5 to $10 ($47 to $94) |
Trimethoprim | 100 mg per day | — | $13 (NA) |
Agents not commonly used for prophylaxis | |||
Ciprofloxacin | 125 mg per day | 125 mg | $9 (NA) |
Fosfomycin (Monurol) | One 3-g packet every 10 days | — | NA ($195 for three packets) |
Ofloxacin | — | 100 mg | $17 (NA) |
note: All regimens have demonstrated an expected frequency of less than one urinary tract infection per year, compared with 0.8 to 3.6 per year with placebo.
NA = not available.
*—Estimated retail price for 30 doses (unless noted otherwise) based on information obtained at http://www.goodrx.com (accessed July 21, 2015). Cost for generic listed first; brand name in parentheses, when available.
Recommended Prophylactic Regimens for Recurrent Urinary Tract Infections
| Medication | Continuous dosage | Postcoital dose | Cost* |
|---|---|---|---|
Commonly used first-line agents | |||
Nitrofurantoin | 50 to 100 mg per day | 100 mg | $29 to $45 (NA) |
Trimethoprim/sulfamethoxazole | 40/200 mg (one-half of an 80/400-mg tablet) per day or 40/200 mg three times per week (alternative) | 40/200 mg or 80/400 mg | $4 to $6 (NA) |
Occasionally used first-line agents | |||
Cefaclor | 250 mg per day | — | $47 (NA) |
Cephalexin (Keflex) | 125 to 250 mg per day | 250 mg | $5 to $10 ($47 to $94) |
Trimethoprim | 100 mg per day | — | $13 (NA) |
Agents not commonly used for prophylaxis | |||
Ciprofloxacin | 125 mg per day | 125 mg | $9 (NA) |
Fosfomycin (Monurol) | One 3-g packet every 10 days | — | NA ($195 for three packets) |
Ofloxacin | — | 100 mg | $17 (NA) |
note: All regimens have demonstrated an expected frequency of less than one urinary tract infection per year, compared with 0.8 to 3.6 per year with placebo.
NA = not available.
*—Estimated retail price for 30 doses (unless noted otherwise) based on information obtained at http://www.goodrx.com (accessed July 21, 2015). Cost for generic listed first; brand name in parentheses, when available.
Are There Alternative Treatment Strategies to Limit Antibiotic Use?
- Abstract
- What Are the Risk Factors for Recurrent UTIs?
- Is Susceptibility to Recurrent UTIs Inherited?
- When Is Further Clinical Evaluation Recommended?
- Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?
- What Are the Benefits of Patient-Initiated Treatment?
- Which Prophylactic Regimens Are Recommended?
- Are There Alternative Treatment Strategies to Limit Antibiotic Use?
- References
A short trial of an analgesic or anti-inflammatory medication for UTI symptoms can limit antibiotic use in willing patients when follow-up is assured. Delaying antibiotic treatment for urinary test results in patients with typical UTI symptoms is not recommended. Prophylaxis with a cranberry product in premenopausal women or topical estrogen therapy in postmenopausal women may limit UTI recurrences and thereby limit antibiotic use, although data about cranberry use are conflicting.
EVIDENCE SUMMARY
A 2009 meta-analysis suggested that symptomatic treatment alone, consisting of a one- to two-day course of a nonsteroidal anti-inflammatory drug (NSAID), is an option in patients with appropriate follow-up because up to one-third of infections resolve spontaneously within one week, with no difference in rates of progression to pyelonephritis.43 However, a recent small study showed a 60% decrease in antibiotic use but a slightly increased risk of pyelonephritis in patients who received ibu-profen.44 No recent or conclusive data exist to support the use of urinary tract analgesics such as phenazopyridine as single-agent treatment for UTI. However, they are generally low-risk medications and may provide analgesic alternatives to NSAIDs.45 Nonetheless, immediate antimicrobial therapy remains the quickest and most effective way to relieve symptoms and provides the best clinical outcomes.11
Delaying antibiotic treatment while awaiting urine dipstick or culture results can limit antibiotic use. However, compared with treatment based on self-diagnosis, this strategy is not preferred because it may increase the number of symptomatic days and cost of diagnosis.11,24,25
Cranberries contain proanthocyanidins, which may prevent adherence of E. coli to uroepithelial cells. Data are conflicting about the effectiveness of cranberry products for preventing recurrent UTI in premenopausal women.46–50 A 2012 meta-analysis demonstrated a decrease in UTI rates in women who received daily cranberry tablets (RR = 0.53; 95% CI, 0.33 to 0.83).48 However, a 2012 Cochrane review found insufficient evidence to recommend routine use of cranberry products for pro-phylaxis.50 They are generally a low-risk intervention and may prove to be another means to reduce UTI episodes and antibiotic use. Appropriate dosing and formulation of cranberry products have not been determined. Dosages of 36 to 72 mg per day are being tested in an ongoing clinical trial.49 Cranberry tablets seem to cause less gastroesophageal reflux and nausea than cranberry juice.46,47
In postmenopausal women, treatment of atrophic vaginitis with topical estrogen formulations may decrease rates of UTI recurrence through effects on vaginal flora.51,52 In a 2008 Cochrane review, women treated with topical estrogen had a 50% reduction in UTI recurrence.52 Oral estrogens are less effective and confer risks associated with systemic hormone replacement, and should not be used for this purpose.51,52
Evidence for intravaginal and oral Lactobacillus probiotics, oral d-mannose, acupuncture, and immunoprophylactic regimens is sparse and conflicting, and further study is warranted.41,46,53
Data Sources: A PubMed search was completed using the MeSH function with the key phrase recurrent urinary tract infections combined with at least one of the following terms: women, non-pregnant, pre-menopausal and post-menopausal. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Also searched were Essential Evidence Plus, the Cochrane Database of Systematic Reviews, the U.S. Preventive Services Task Force website, and relevant recommendations from the Infectious Diseases Society of America and the European Society of Clinical Microbiology and Infectious Diseases. Search dates: October 1, 2014, to February 14, 2016.
The authors thank Margaret Freiberg for her assistance in the preparation of the manuscript.
The opinions and assertions contained herein are the personal views of the authors and are not to be construed as official or as reflecting the views of the U.S. armed services or their medical departments.
REFERENCES
show all references1. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–e120....
2. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1–13.
3. Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ. 2013;346:f3140.
4. Raz R. Urinary tract infection in postmenopausal women. Korean J Urol. 2011;52(12):801–808.
5. Glover M, Moreira CG, Sperandio V, Zimmern P. Recurrent urinary tract infections in healthy and nonpregnant women. Urol Sci. 2014;25(1):1–8.
6. Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000;182(4):1177–1182.
7. Scholes D, Hawn TR, Roberts PL, et al. Family history and risk of recurrent cystitis and pyelonephritis in women. J Urol. 2010;184(2):564–569.
8. Hooton TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med. 1996;335(7):468–474.
9. Raz R, Gennesin Y, Wasser J, et al. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis. 2000;30(1):152–156.
10. Zhong YH, Fang Y, Zhou JZ, Tang Y, Gong SM, Ding XQ. Effectiveness and safety of patient initiated single-dose versus continuous low-dose antibiotic prophylaxis for recurrent urinary tract infections in post-menopausal women: a randomized controlled study. J Int Med Res. 2011;39(6):2335–2343.
11. Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014;312(16):1677–1684.
12. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012;366(11):1028–1037.
13. McIsaac WJ, Moineddin R, Ross S. Validation of a decision aid to assist physicians in reducing unnecessary antibiotic drug use for acute cystitis. Arch Intern Med. 2007;167(20):2201–2206.
14. Hickling DR, Nitti VW. Management of recurrent urinary tract infections in healthy adult women. Rev Urol. 2013;15(2):41–48.
15. Schaeffer AJ, Stuppy BA. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol. 1999;161(1):207–211.
16. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004(3):CD001209.
17. Suskind AM, Saigal CS, Hanley JM, Lai J, Setodji CM, Clemens JQ; Urologic Diseases of America Project. Incidence and management of uncomplicated recurrent urinary tract infections in a national sample of women in the United States. Urology. In press.
18. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002;287(20):2701–2710.
19. Wong ES, McKevitt M, Running K, Counts GW, Turck M, Stamm WE. Management of recurrent urinary tract infections with patient-administered single-dose therapy. Ann Intern Med. 1985;102(3):302–307.
20. Schmiemann G, Kniehl E, Gebhardt K, Matejczyk MM, Hummers-Pradier E. The diagnosis of urinary tract infection: a systematic review. Dtsch Arztebl Int. 2010;107(21):361–367.
21. Knottnerus BJ, Geerlings SE, Moll van Charante EP, Ter Riet G. Toward a simple diagnostic index for acute uncomplicated urinary tract infections. Ann Fam Med. 2013;11(5):442–451.
22. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013;369(20):1883–1891.
23. Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J. 2011;5(5):316–322.
24. Fenwick EA, Briggs AH, Hawke CI. Management of urinary tract infection in general practice: a cost-effectiveness analysis. Br J Gen Pract. 2000;50(457):635–639.
25. Little P, Moore MV, Turner S, et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ. 2010;340:c199.
26. van Haarst EP, van Andel G, Heldeweg EA, Schlatmann TJ, van der Horst HJ. Evaluation of the diagnostic workup in young women referred for recurrent lower urinary tract infections. Urology. 2001;57(6):1068–1072.
27. Nickel JC, Wilson J, Morales A, Heaton J. Value of urologic investigation in a targeted group of women with recurrent urinary tract infections. Can J Surg. 1991;34(6):591–594.
28. Lawrentschuk N, Ooi J, Pang A, Naidu KS, Bolton DM. Cytoscopy in women with recurrent urinary tract infection. Int J Urol. 2006;13(4):350–353.
29. Lutters M, Vogt-Ferrier NB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev. 2008(3):CD001535.
30. Milo G, Katchman EA, Paul M, Christiaens T, Baerheim A, Leibovici L. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev. 2005(2):CD004682.
31. Katchman EA, Milo G, Paul M, Christiaens T, Baerheim A, Leibovici L. Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis. Am J Med. 2005;118(11):1196–1207.
32. Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(9):1862–1877.
33. Amna MA, Chazan B, Raz R, Edelstein H, Colodner R. Risk factors for non- Escherichia coli community-acquired bacteriuria. Infection. 2013;41(2):473–477.
34. Schito GC, Naber KG, Botto H, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34(5):407–413.
35. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012;56(4):2181–2183.
36. Lexi-Comp. https://online.lexi.com/crlsql/servlet/crlon-line [subscription required]. Accessed December 30, 2014.
37. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM; Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults [published correction appears in Clin Infect Dis. 2005;40(10):1556]. Clin Infect Dis. 2005;40(5):643–654.
38. Cai T, Mazzoli S, Mondaini N, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis. 2012;55(6):771–777.
39. Schneeberger C, Kazemier BM, Geerlings SE. Asymptomatic bacteriuria and urinary tract infections in special patient groups: women with diabetes mellitus and pregnant women. Curr Opin Infect Dis. 2014;27(1):108–114.
40. Wang MC, Tseng CC, Wu AB, et al. Bacterial characteristics and glycemic control in diabetic patients with Escherichia coli urinary tract infection. J Microbiol Immunol Infect. 2013;46(1):24–29.
41. Geerlings SE. Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. Int J Antimicrob Agents. 2008;31(suppl 1):S54–S57.
42. Eells SJ, Bharadwa K, McKinnell JA, Miller LG. Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. Clin Infect Dis. 2014;58(2):147–160.
43. Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect. 2009;58(2):91–102.
44. Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015;351:h6544.
45. Kirwin TJ, Lowsley OS, Menning J. The effects of pyridium in certain urogenital infections. Am J Surg. 1943;62(2):330–335.
46. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013;190(6):1981–1989.
47. Hisano M, Bruschini H, Nicodemo AC, Srougi M. Cranberries and lower urinary tract infection prevention. Clinics (Sao Paulo). 2012;67(6):661–668.
48. Wang CH, Fang CC, Chen NC, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(13):988–996.
49. National Institutes of Health. Effects of cranberry-containing products in women with recurrent urinary tract infections (UTIs). http://clinicaltrials.gov/ct2/show/record/NCT00100061. Accessed December 30, 2014.
50. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012(10):CD001321.
51. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753–756.
52. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008(2):CD005131.
53. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015(12):CD008772.
Copyright © 2016 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact
afpserv@aafp.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
Editor's Collections
Related Content
More in Pubmed
MOST RECENT ISSUE
Email Alerts
Don't miss a single issue. Sign up for the free AFP email table of contents.
